Cross-sectional and longitudinal relation of IGF1 and IGF-binding protein 3 with lipid metabolism

European Journal of Endocrinology

Volumn 171, Issue 1, 2014, Pages 9-19

  Eggert, Marie Luise ^a   Wallaschofski, Henri ^a,b   Grotevendt, Anne ^a   Nauck, Matthias ^a,b   Völzke, Henry ^a,b   Samietz, Stefanie ^a   Friedrich, Nele ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANALYSIS OF VARIANCE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SENSITIVITY ANALYSIS; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; WAIST CIRCUMFERENCE;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84903547970     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-1017     Document Type: Article

References (40)

1. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Hormone & IGF Research 2003 13 113-170. (doi:10.1016/S1096-6374(03)00038-8)
2. Jones JI & Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995 16 3-34.
3. Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D & Wilson PW. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Annals of Internal Medicine 2003 139 642-648. (doi:10.7326/0003-4819-139-8-200310210-00007)
4. Juul A, Scheike T, Davidsen M, Gyllenborg J & Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002 106 939-944. (doi:10.1161/01.CIR.0000027563.44593.CC)
5. Burgers AM, Biermasz NR, Schoones JW, Pereira AM, Renehan AG, Zwahlen M, Egger M & Dekkers OM. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. Journal of Clinical Endocrinology and Metabolism 2011 96 2912-2920. (doi:10.1210/jc.2011- 1377)
6. Graham I, Cooney MT, Bradley D, Dudina A & Reiner Z. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Current Cardiology Reports 2012 14 709-720. (doi:10.1007/s11886-012-0313-7)
7. Friedrich N, Thuesen B, Jorgensen T, Juul A, Spielhagen C, Wallaschofksi H & Linneberg A. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 2012 35 768-773. (doi:10.2337/dc11-1833)
8. Friedrich N, NauckM, Schipf S, Volzke H, Brabant G & Wallaschofski H. Cross-sectional and longitudinal associations between insulin-like growth factor I and metabolic syndrome: a general population study in German adults. Diabetes/Metabolism Research and Reviews 2013 29 452-462. (doi:10.1002/dmrr. 2412)
9. Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Malarstig A, Brismar K, Hamsten A, Fisher RM & Hellenius ML. IGF-I/IGFBP-3 ratio: a mechanistic insight into themetabolic syndrome. Clinical Science 2009 116 507-512. (doi:10.1042/CS20080382)
10. Colao A, di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M & Lombardi G. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. Journal of Clinical Endocrinology and Metabolism 2001 86 1874-1881.
11. Kim ES, Park JH, Lee MK, Lee DH, Kang ES, Lee HC, Jekal Y & Jeon JY. Associations between fatness, fitness, IGF and IMT among obese Korean male adolescents. Diabetes & Metabolism 2011 35 610-618. (doi:10.4093/dmj.2011. 35.6.610)
12. Lam CS, Chen MH, Lacey SM, Yang Q, Sullivan LM, Xanthakis V, Safa R, Smith HM, Peng X, Sawyer DB et al. Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 1479-1484. (doi:10.1161/ATVBAHA.110.203943)
13. Nyström FH, Ohman PK, Ekman BA, Osterlund MK, Karlberg BE & Arnqvist HJ. Population-based reference values for IGF-I and IGF-binding protein-1: relations with metabolic and anthropometric variables. European Journal of Endocrinology 1997 136 165-172. (doi:10.1530/eje.0.1360165)
14. Barbosa EJ, Glad CA, Nilsson AG, Filipsson Nyström H, Gotherstrom G, Svensson PA, Vinotti I, Bengtsson BA, Nilsson S, Boguszewski CL et al. Genotypes associated with lipid metabolism contribute to differences in serum lipid profile of GH-deficient adults before and after GH replacement therapy. European Journal of Endocrinology 2012 167 353-362. (doi:10.1530/EJE-12-0263)
15. Ceda GP, Dall'Aglio E, Magnacavallo A, Vargas N, Fontana V, Maggio M, Valenti G, Lee PD, Hintz RL & Hoffman AR. The insulin-like growth factor axis and plasma lipid levels in the elderly. Journal of Clinical Endocrinology and Metabolism 1998 83 499-502.
16. de Boer H, Blok GJ, Voerman HJ, Phillips M & Schouten JA. Serum lipid levels in growth hormone-deficient men. Metabolism 1994 43 199-203. (doi:10.1016/0026-0495(94)90245-3)
17. Fideleff HL, Jonsson B, Koltowska-Haggstrom M, Boguszewski MC, Wilton P & Boquete HR. GH deficiency during the transition period: clinical characteristics before and after GH replacement therapy in two different subgroups of patients. Journal of Pediatric Endocrinology & Metabolism 2012 25 97-105. (doi:10.1515/jpem.2011.349)
18. Filipsson Nyström H, Barbosa EJ, Nilsson AG, Norrman LL, Ragnarsson O & Johannsson G. Discontinuing long-term GH replacement therapy-A randomized, placebo-controlled crossover trial in adult GH deficiency. Journal of Clinical Endocrinology and Metabolism 2012 97 3185-3195. (doi:10.1210/jc. 2012-2006)
19. Rosen T, Eden S, Larson G, Wilhelmsen L & Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinologica 1993 129 195-200.
20. Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Goth MI, Wilton P & Koltowska-Haggstrom M. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults-A KIMS database analysis. European Journal of Endocrinology 2006 155 79-90. (doi:10.1530/eje.1.02179)
21. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G & Manzato E. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 2000 151 551-557. (doi:10.1016/S0021-9150(99)00426-8)
22. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O & Faglia G. Effects of treatment with octreotide in acromegalic patients-A multicenter Italian study. Italian Multicenter Octreotide Study Group. European Journal of Endocrinology 1995 133 430-439. (doi:10.1530/eje.0.1330430)
23. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S & Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 2011 14 284-294. (doi:10.1007/s11102-011-0310-7)
24. John U, Greiner B, Hensel E, Ludemann J, Piek M, Sauer S, Adam C, Born G, Alte D, Greiser E et al. Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Sozial-und Präventivmedizin 2001 46 186-194. (doi:10.1007/BF01324255)
25. Bühringer G, Augustin R, Bergmann E, Bloomfield K, Funk W, Junge B, Kraus L, Merfert-Diete C, Rumpf H-J, Simon R et al. Alkoholkonsum und Alkoholbezogene Störungen in Deutschland [Alcohol consumption and alcoholrelated problems in Germany]. Baden-Baden: Nomos Verlagsgesellschaft, 2002.
26. Nauck M, Winkler K, Marz W & Wieland H. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clinical Chemistry 1995 41 1761-1767.
27. Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
28. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 3143-3421.
29. Report of a WHO consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva World Health Organization, 1999.
30. Völzke H, Alte D, Kohlmann T, Ludemann J, Nauck M, John U & Meng W. Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid 2005 15 279-285. (doi:10.1089/thy.2005.15.279)
31. Stone C & Koo CY. Additive splines in statistics. In Proceedings of the Statistical Computing Section, pp 45-48. Washington, DC: American Statistical Association, 1985.
32. Clarke KA. Testing nonnested models of international relations: reevaluating realism. American Journal of Political Science 2001 45 724-744. (doi:10.2307/2669248)
33. Colao A, Di Somma C, Savastano S, Rota F, Savanelli MC, Aimaretti G & Lombardi G. A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. Journal of Clinical Endocrinology and Metabolism 2009 94 4414-4422. (doi:10.1210/jc.2009-1134)
34. Maldonado Castro GF, Escobar-Morreale HF, Ortega H, Gomez-Coronado D, Balsa Barro JA, Varela C & Lasuncion MA. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. Clinical Endocrinology 2000 53 313-319. (doi:10.1046/j.1365-2265. 2000.01092.x)
35. Mauras N, O'Brien KO, Welch S, Rini A, Helgeson K, Vieira NE & Yergey AL. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. Journal of Clinical Endocrinology and Metabolism 2000 85 1686-1694.
36. Götherström G, Bengtsson BA, Bosaeus I, Johannsson G & Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. Journal of Clinical Endocrinology and Metabolism 2007 92 1442-1445. (doi:10.1210/jc.2006-1487)
37. Johannsson G, Oscarsson J, Rosen T, Wiklund O, Olsson G, Wilhelmsen L & Bengtsson BA. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Arteriosclerosis, Thrombosis, and Vascular Biology 1995 15 2142-2150. (doi:10.1161/01.ATV.15.12.2142)
38. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N & Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Annals of Internal Medicine 2000 133 111-122. (doi:10.7326/0003-4819-133-2-200007180-00010)
39. Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 1754-1759. (doi:10.1161/ATVBAHA.111.241885)
40. Friedrich N, Haring R, Nauck M, Lüdemann J, Rosskopf D, Spilcke-Liss E, Felix SB, Dörr M, Brabant G, Völzke H et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. Journal of Clinical Endocrinology and Metabolism 2009 94 1732-1739. (doi:10.1210/jc.2008-2138)